CASE REPORT
Rituximab-induced neutropenia in a patient with inflammatory myopathy and systemic sclerosis overlap disease
Submission date: 2015-12-10
Acceptance date: 2016-01-31
Online publication date: 2016-03-24
Publication date: 2016-02-29
Reumatologia 2016;54(1):35-37
KEYWORDS
TOPICS
Scleroderma, myositis and related syndromes - aetiology, pathogenesis, clinical features and treatmentLetter to the editor
ABSTRACT
Rituximab (RTX) is a monoclonal chimeric antibody directed against the CD20 antigen of B lymphocytes. Late onset neutropenia (LON) is a recognised complication of rituximab usually occurring 4 weeks after the last dose and is reported in both haematological and rheumatological conditions. However, it has never been described in a patient with myositis and systemic sclerosis overlap disease.We describe a case of LON in a 54-year-old man who was diagnosed with myositis and then systemic sclerosis overlap disease. It resolved within 7 days, and the patient did not suffer neutropenic sepsis or any other complications. We propose similar mechanisms for LON as described in other conditions and routine blood monitoring in such patients.
REFERENCES (7)
1.
Breuer G, Ehrenfeld M, Rosner I, et al. Late onset neutropenia following rituximab for rheumatic conditions. Clin Rheumatol 2014; 33: 1337-1340.
2.
Oddis CV, Reed AM, Aggarwal R, et al.; RIM Study Group. Rituximab in the Treatment of Refractory Adult and Juvenile Dermatomyositis and Adult Polymyositis A Randomized, Placebo-Phase Trial. Arthritis Rheum 2013; 65: 314-324.
3.
Rider LG, Giannini EH, Harris-Love M, et al.; International Myositis Assessment and Clinical Studies Group. Defining Clinical Improvement in Adult and Juvenile Myositis. J Rheumatol 2003; 30: 603-617.
4.
De Groot K, Muhler M, Reinhold-Keller E, et al. Randomised controlled trial of daily oral versus pulsed cyclophosphamide for induction of remission in ANCA associated systemic vasculitis (abstract). Kidney Blood Pressure Res 2005; 28: 195.
5.
Emery P, Rigby WF, Combe B, et al. Efficacy and safety of rituximab (RTX) as first-line biologic therapy in patients with active rheumatoid arthritis (RA): results of a phase III randomized controlled study (SERENE). Arthritis Rheum 2008; 58: S302.
6.
Besada E, Koldingsnes W, Nossent J. Characteristics of late onset neutropenia in rheumatology patients: a case review analysis from a single centre. QJ Med 2012; 105: 545-560.
7.
Tesfa D, Ajeganova S, Hagglund H, et al. Late onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections. Arthritis Rheum 2011; 63: 2209-2214.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Share
RELATED ARTICLE
| eISSN: | 2084-9834 |
| ISSN: | 0034-6233 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
